BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 36305410)

  • 21. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
    Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
    Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel prognostic targets in glioblastoma using bioinformatics analysis.
    Yin X; Wu Q; Hao Z; Chen L
    Biomed Eng Online; 2022 Apr; 21(1):26. PubMed ID: 35436915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.
    Noor H; Whittaker S; McDonald KL
    Genomics; 2022 Mar; 114(2):110289. PubMed ID: 35124175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment.
    Jia D; Li S; Li D; Xue H; Yang D; Liu Y
    Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis.
    Zhang H; Bao M; Liao D; Zhang Z; Tian Z; Yang E; Luo P; Jiang X
    Med Oncol; 2023 Apr; 40(6):161. PubMed ID: 37099121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
    Han Z; Jia J; Lv Y; Wang R; Cao K
    Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.
    Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ
    Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma.
    Liu M; Liang W; Su Y; Wen Y; Qi J; Wang L; Su S; Zhao J; Shan J; Wang J
    Exp Cell Res; 2024 Jun; 439(1):114076. PubMed ID: 38719174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
    Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
    Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 34. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FCGR2B as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis.
    Sun Z; Sun X; Yuan Y; Li H; Li X; Yao Z
    Medicine (Baltimore); 2023 Sep; 102(37):e35084. PubMed ID: 37713871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptor Protein Complex 1 Sigma 3 Is Highly Expressed in Glioma and Could Enhance Its Progression.
    Ye T; Cheng Y; Li C
    Comput Math Methods Med; 2021; 2021():5086236. PubMed ID: 34367317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of m
    Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
    Front Immunol; 2022; 13():955848. PubMed ID: 36203569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EPHB2 as a key mediator of glioma progression: Insights from microenvironmental receptor ligand-related prognostic gene signature.
    Tan L; Zhou J; Nie Z; Li D; Wang B
    Genomics; 2024 May; 116(3):110799. PubMed ID: 38286348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
    Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
    Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.